Press Releases.

Accelerates RG-101 for HCV with Dual-Track Clinical Development Strategy; Top-Line, Single Dose, 4 mg/kg Results as Well as 2mg/kg Extended Follow Up Results from Ongoing Study to be Reported in Early February 2015

- Treatment with RG-012 Protects Kidney Function and Demonstrates Additive Therapeutic Effect with Emerging Standard of Care in Preclinical Model of Alport Syndrome -

- Demonstrated Human Proof-of-Concept; 'Clinical Map Initiative' Updated -

- Interim Results from Ongoing Study Demonstrate Human Proof-of-Concept and Underscore the Value of Regulus' microRNA Platform -

-New Preclinical Results Increase Mechanistic Understanding of Targeting miR-103/107 for Metabolic Disorders and miR-21 for Renal Dysfunction in Alport Syndrome Patients-

-Newly Allowed Claims Demonstrate Regulus' Leadership in the microRNA Field-

-ATHENA to Shed Light on Rare, Life-Threatening Kidney Disease -

- 'Clinical Map Initiative' On Track; Human Proof of Concept Results for RG-101 and Nomination of Third Clinical Candidate Expected by YE 2014 -

- New Method of Use Claims Strengthen Patent Estate Covering microRNA-122 Inhibitors for the Treatment of HCV Infection -

- Recognized Industry Leader Brings Extensive Clinical and Product Development Expertise -

- 'Clinical Map Initiative' On Track; Advanced RG-101 and RG-012, Expect to Nominate Third microRNA Clinical Candidate by YE 2014 -

- Data Advances microRNA Oncology Portfolio -